Last reviewed · How we verify
Insulin 320
At a glance
| Generic name | Insulin 320 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HbA1c Variability in Type II Diabetes (NA)
- Evaluation Study of New Compounds With Potential Use in Schizophrenia (PHASE1)
- EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY (PHASE1)
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome (PHASE4)
- A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects (PHASE1)
- Comparative Trial Between 3 Types of Insulin Infusion Protocols (NA)
- Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (PHASE4)
- Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin 320 CI brief — competitive landscape report
- Insulin 320 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI